Gilead Sciences (GILD) Total Debt (2009 - 2026)
Gilead Sciences' (GILD) quarterly Total Debt came in at $22.2 billion in Q1 2026, down 20.12% YoY from $27.8 billion in Q1 2025, and down 11.08% on a QoQ basis from $24.9 billion in Q4 2025.
Gilead Sciences (GILD) Total Debt (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Total Debt data on file, last reported at $22.2 billion in Q1 2026.
- Quarterly Total Debt fell 20.12% year-over-year to $22.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.2 billion (down 20.12% YoY) and the FY2025 annual result came in at $24.9 billion, down 6.65% from the prior year.
- Total Debt eased to $22.2 billion in Q1 2026, from $24.9 billion in the prior quarter.
- In the past five years, Total Debt ranged from a high of $29.3 billion in Q2 2023 to a low of $22.2 billion in Q1 2026.
- A 5-year average of $26.0 billion and a median of $25.2 billion in 2023 frame the typical range for Total Debt.
- Annual changes were most pronounced in 2025 — Total Debt increased 10.31% — and 2026, when it slipped 20.12%.
- Tracing GILD's Total Debt over 5 years: stood at $25.2 billion in 2022, then grew by 6.16% to $26.8 billion in 2023, then declined by 0.28% to $26.7 billion in 2024, then dropped by 6.65% to $24.9 billion in 2025, then declined by 11.08% to $22.2 billion in 2026.
- The last three Total Debt figures came in at $22.2 billion (Q1 2026), $24.9 billion (Q4 2025), and $24.9 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 49.04 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 70.82 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 53.91 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 9.59 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 29.49 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 62.75 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 28.66 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 63.19 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -25.96 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 25.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.66 Bn |
| Mar 31, 2026 | 22.17 Bn |
| Dec 31, 2025 | 24.94 Bn |
| Sep 30, 2025 | 24.94 Bn |
| Jun 30, 2025 | 27.75 Bn |
| Mar 31, 2025 | 27.76 Bn |
| Dec 31, 2024 | 26.71 Bn |
| Sep 30, 2024 | 25.06 Bn |
| Jun 30, 2024 | 25.16 Bn |
| Mar 31, 2024 | 25.19 Bn |
| Dec 31, 2023 | 26.79 Bn |
| Sep 30, 2023 | 26.78 Bn |
| Jun 30, 2023 | 29.28 Bn |
| Mar 31, 2023 | 25.24 Bn |
| Dec 31, 2022 | 25.23 Bn |
| Sep 30, 2022 | 25.22 Bn |
| Jun 30, 2022 | 27.24 Bn |
| Mar 31, 2022 | 26.21 Bn |
| Dec 31, 2021 | 28.21 Bn |
| Sep 30, 2021 | 30.20 Bn |